Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

reduced potassium secretion1 - attention deficit hyperactivity disorder1 - treatment of prostate cancer1 - radical prostatectomy9 - robotic-assisted radical prostatectomy1 - hormone treatment1 - renal cells2 - polyarteritis nodosa1 - microrna1 - pelvic circulation1 - fighting1 - tubular ectasia1 - urine culture3 - annual screening1 - vytorin1 - gonococcal infections1 - renal abnormalities1 - trichomoniasis1 - rituximab1 - urine incontinence1 - anorectal canal1 - kidney failure37 - birth control2 - local recurrence1 - urinary tract defects1 - kidney cancer10 - hypoalbuminemia1 - kidney's artery1 - metastatic tumors1 - high glucose1 -